Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTIS-5
2023-503916-33-00Phase 3Completed
- Sponsor
- ADC Therapeutics
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of loncastuximab tesirine and rituximab in diffuse large B-cell lymphoma (DLBCL) and large-cell lymphoma (2 arms), sponsored by ADC Therapeutics. Primary endpoint: Progression-free survival. Started Mar 2021; status: completed.
02
Drugs
loncastuximab tesirinerituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphoma
Beyond the preview
Go deeper on 2023-503916-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503916-33-00.